MedTrace Logo

Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy

NCT00655330 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2016-08-24

No results posted yet for this study

Summary

This is a prospective randomized controlled, open-labeled study to identify the efficacy of probucol in combination with valsartan in patients with Diabetes nephropathy. The reduction of urinary albumin or proteinuria will be the primary outcome studied. The expected study duration will be 48 weeks.

Conditions

Interventions

DRUG

Valsartan

Valsartan (160mg/day)

DRUG

Placebo

Placebo

DRUG

Probucol

Probucol (750mg/day)

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    lead OTHER

Principal Investigators

  • Shi Wei, MD, PhD · Nephrology Dept.,Guangdong General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00655330 on ClinicalTrials.gov